Investment Portfolio — 2026

Where capital meets capability that ships.

SmartMindsWorld builds, backs and advises companies at the edge of applied intelligence and health technology. Several of them are raising. This page sets out what each one does, the sector and market it plays in, the stage it has reached, and how a prospective investor engages with us.

See the companies Request the investor pack

Portfolio at a glance SMW-INV-01 Nov 2026

Companies in the active portfolio, across venture, partner and advisory positions

Sectors: applied AI, regulated medical devices, digital health delivery

Markets: Australia, New Zealand, India and wider APJ, with MEA pathways open

Pre-seed → growth

Stage range we hold positions in, from research-stage through commercial scale-up

One operating bench behind every position — engineering, regulatory and commercial, carried into each company we put our name on.

How we pick

Regulated upside

We favour companies whose moat is hard to copy: clinical evidence, device approvals, quality systems and data that took years to assemble. Regulatory difficulty is a feature, not a tax.

Cross-border by design

India and ANZ are our two home bases. We back businesses that can earn in one market and manufacture, engineer or distribute from the other, with the trade and regulatory path already mapped.

Operators, not spectators

Every position comes with hands on the work — cloud architecture, quality management, commercial strategy, partner channels. We are inside these companies, not watching them from a spreadsheet.

The portfolio

Five companies, one bench

Portfolio summary — November 2026
Company	Sector	Primary market	Stage	Our position	Raising
GetSmartMinds.AI	Applied AI & cloud	Australia, NZ, APJ	Operating, scaling	Group venture	Growth capital
Arjanam.com	Medical device sourcing & export	India → ANZ, MEA, SEA	Early operations	Group venture	Seed
Advenio TecnoSys	Clinical AI (SaMD)	India, APJ	Commercial launch	Strategic partner	Scale-up round
AVOORA Technologies	Digital health engagement	Australia	Seed	Board advisory	Seed close
SG ArtHeart	Implantable medical device	India, global licensing	Research stage	Commercial advisory	Pre-seed / grant

Round sizes, instruments and terms are not published here. They are set out company by company in the investor pack, released to qualifying investors on request.

Company profiles

Position 01 Group venture Applied AI

GetSmartMinds.AI

The group's applied-intelligence arm. GetSmartMinds.AI puts a working AI and cloud team inside a client's business — models, agents and engineering that plug into the systems they already run and start producing from the first sprint. It is also an AWS partner on the Tech Data acceleration program, working through Select tier toward Advanced with AI competency, which gives it a funded route to market most AI services firms do not have.

Investment case

Revenue today, not a pilot pipeline — delivery engagements across APJ already billing
Hyperscaler partner status turns cloud migration funding into a demand channel rather than a cost
Migration-factory delivery model: the same playbook runs across customers, so margin improves with volume
Acts as the engineering bench for the rest of the portfolio, compounding group capability

Use of funds

Delivery capacity — senior cloud and AI engineers across Australia and India
Partner tier progression and competency certification
Productising the repeatable parts of delivery into licensable platform assets

Key information

SectorApplied AI & cloud services
StageOperating, scaling
MarketsAU, NZ, India, APJ
ModelServices + platform
Raising forGrowth capital
SMW roleFounding venture
StatusRevenue generating

Position 02 Group venture Medtech trade

Arjanam.com

A cross-border medtech trade platform. Arjanam sources medical devices, consumables, services and software from Indian manufacturers and exports them to the rest of the world — starting with Australia and New Zealand, the Middle East and Africa, and South East Asia. India has world-class device manufacturing and a thin layer of operators who can clear regulatory, quality and distribution hurdles in the destination market. Arjanam is built to be that layer.

Investment case

Structural cost arbitrage in a market where buyers are under permanent margin pressure
Regulatory and quality capability in-house, which is the real barrier to entry, not sourcing
Asset-light model: demand validated before category commitment, across three regions in parallel
Ambition is category leadership in Indian device distribution, in a field where comparable operators have already proven the model

Use of funds

Working capital for first committed supply contracts
Regulatory registration and in-market approvals per target geography
Platform build — supplier catalogue, compliance records, buyer ordering

Key information

SectorDevice sourcing & export
StageEarly operations
Source marketIndia
Target marketsANZ, MEA, SEA
Raising forSeed
SMW roleFounding venture
StatusSupplier & buyer pipeline live

Position 03 Strategic partner Clinical AI

Advenio TecnoSys

An independent software vendor in Kolkata, India, and the company behind Adven-i — an AI teleophthalmology platform classified as software as a medical device, reading fundus images for diagnostic screening. Diabetic retinopathy and related eye disease are mass-scale, under-screened conditions, and ophthalmologist supply will never meet the need. Advenio's product is past the research question and into the deployment question.

Investment case

SaMD classification and a design history file already built — the slow, expensive part is behind it
Screening economics work in exactly the markets with the largest undiagnosed populations
Cloud migration to AWS underway with SmartMindsWorld, removing the scale ceiling of on-premise infrastructure
Co-sell route to market through a joint hyperscaler partner structure rather than direct-sales-only

Use of funds

Platform modernisation and regulated-health cloud landing zone
Clinical and generative AI capability extension
Market expansion beyond India into wider APJ screening programs

Key information

SectorClinical AI / SaMD
ProductAdven-i teleophthalmology
StageCommercial launch
BaseKolkata, India
Raising forScale-up round
SMW roleTechnology & co-sell partner
StatusAWS migration in progress

Position 04 Board advisory Digital health

AVOORA Technologies

An AI-powered patient engagement platform operating in Australia. AVOORA sits in the gap between the clinic and the patient at home — the stretch where adherence, follow-up and outcome data all leak away. Health systems are being paid increasingly on outcomes rather than episodes, which makes engagement infrastructure a budget line rather than a nice-to-have.

Investment case

Clear buyer and clear budget as Australian health funding shifts toward outcome-linked models
Product in market, with cloud migration to AWS underway alongside the group
Governance being built ahead of scale — board advisory in place, directorship and D&O sequenced to the seed close
Adjacent to the group's device and clinical AI positions, giving distribution leverage

Use of funds

Runway to commercial milestones ahead of the next round
Infrastructure migration and security posture for health-data workloads
Sales capability against provider and payer buyers

Key information

SectorDigital health engagement
StageSeed
MarketAustralia
ModelSaaS, provider-paid
Raising forSeed close
SMW roleIndependent board advisory
StatusIn market, raising

Position 05 Commercial advisory Implantable device

SG ArtHeart

A research-stage venture developing a keyhole replaceable artificial heart, linked to SGT University in Gurgaon, India. Current total artificial heart and ventricular assist technology demands major open surgery and, when a device fails, demands it again. A keyhole-replaceable architecture changes both the implantation risk and the device's whole-of-life economics. This is the longest-dated and highest-variance position in the portfolio, and it is presented as such.

Investment case

Addresses the replacement problem, not only the implantation problem — a genuine architectural difference
University-linked research base with access to engineering and clinical collaboration
Twin funding path: private capital for commercial development, institutional grants for the research program
Indian development cost base against a global cardiac device market

Use of funds

Prototype development and bench validation
Pre-clinical program and regulatory strategy
Intellectual property position and freedom-to-operate work

Risk note. Research-stage implantable cardiac devices carry long development timelines, substantial regulatory risk and a high probability of capital loss. This position suits investors with device-sector experience and a long holding horizon.

Key information

SectorImplantable cardiac device
StageResearch stage
BaseGurgaon, India
AffiliationSGT University
Raising forPre-seed / grant
SMW roleCommercial advisory
Risk profileHigh / long-dated

How the process runs

From first call to committed

Qualify and brief

A short call to confirm mandate fit, investor classification and which positions are relevant. You get the portfolio brief and the company one-pagers that match.

Data room access

Under NDA, access to the company's data room: financials, regulatory status, technology and architecture documentation, cap table and the current round terms.

Management and terms

Direct sessions with founders and management, technical deep dives where you want them, then terms negotiated with the company. We stay involved through close and after it.

Investor questions

Who can invest through SmartMindsWorld?

We work with wholesale, sophisticated and professional investors as those terms are defined in the relevant jurisdiction, along with family offices, strategic corporates and institutional funds. We are not set up for retail offers, and nothing on this page is directed at retail investors.

Do you invest alongside the companies you introduce?

It varies by position, and we tell you which is which. GetSmartMinds.AI and Arjanam.com are our own ventures. Advenio is a strategic and commercial partner. AVOORA and SG ArtHeart are advisory engagements. Our interest in each one is disclosed in writing before any introduction.

Why aren't round sizes and valuations on this page?

Because they move, and because publishing live terms on an open web page is the wrong way to run a raise. Round size, instrument, committed amount and valuation are set out per company in the investor pack, which is released on request to qualifying investors under NDA.

What does SmartMindsWorld bring beyond capital introductions?

An operating bench. Cloud and AI engineering, quality management and ISO-grade documentation, regulatory pathway work, AWS partner funding routes and commercial strategy. In most of these companies we are doing the work, not reviewing it, which is also why our diligence view on them is a first-hand one.

Can we invest in a single company rather than the portfolio?

Yes. Each position is a direct investment into that company on its own terms. There is no pooled fund vehicle, and we are not offering an interest in a managed investment scheme.

Investor relations

Request the investor pack.

Tell us who you are and which positions interest you. Qualifying investors receive the portfolio brief and the relevant company materials, usually within one business day. Data room access follows an NDA.

Full name

Firm or family office

Phone (optional)

Investor type

Position of interest

Indicative ticket size

Anything we should know

I confirm I am not a retail investor in my jurisdiction, and I understand this page is information only and not an offer of securities.

Your details are used only to respond to this request. We do not sell or share them.

Important information

This page is provided for general information only. It is not an offer, invitation or recommendation to buy, sell or subscribe for securities or any other financial product, and it is not financial product advice. It does not take into account any person's objectives, financial situation or needs.

Nothing here constitutes a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (Cth) or the equivalent legislation of any other jurisdiction. Any investment opportunity referred to is available only to investors who qualify as wholesale, sophisticated, professional or accredited investors under the law applying to them, and only on the terms of the offer documents issued by the relevant company.

SmartMindsWorld holds differing interests across the companies described: some are group ventures, others are commercial partners or advisory clients. The nature of our interest in each company, and any fee or equity arrangement connected with a capital raising, is disclosed in writing before any introduction is made. SmartMindsWorld is not a licensed financial adviser and does not provide financial product advice.

Forward-looking statements about development plans, regulatory pathways, markets or growth are estimates based on current expectations and carry risk. Early-stage and research-stage companies, and medical device companies in particular, involve a high risk of total capital loss. Past performance is not a guide to future performance. Prospective investors should obtain independent legal, financial and taxation advice and conduct their own due diligence before making any investment decision.